| Literature DB >> 28935854 |
Valentina Lancellotta1, Martina Iacco2, Elisabetta Perrucci3, Claudio Zucchetti2, Anna Concetta Dipilato2, Lorenzo Falcinelli3, Isabella Palumbo4, Cynthia Aristei4.
Abstract
BACKGROUND Synchronous bilateral breast cancer is rare. A case is presented where whole breast irradiation (WBI) was planned after breast conserving surgery in a patient with synchronous bilateral breast cancer. A comparison was made between the feasibility of helical tomotherapy and direct tomotherapy. CASE REPORT A 60-year-old woman was found to have bilateral breast nodules on routine mammographic screening, resulting in bilateral lumpectomy and sentinel lymph node biopsy. Histopathology showed a 6 mm diameter invasive ductal carcinoma in the right breast (Grade 1, hormone receptor positive, HER2 negative) and an 8mm diameter tubular carcinoma in the left breast (Grade 1, hormone receptor positive, HER2 negative). Lymph node biopsy and histology, chest X-ray, abdominal ultrasound scan, and bone scintigraphy were negative for metastases (both tumors were Stage 1). Adjuvant therapy with commenced with anastrozole, but no chemotherapy was given. Clinical target volumes (CTVs) were contoured on computed tomography (CT) images. For planning target volumes (PTVs), CTVs were expanded by 1 cm in all directions, except for the medial 5 mm. Since dose constraints to organs at risk (OARs) were beyond established limits, CTVs were expanded by 5 mm. For PTVs, OAR doses and homogeneity indices for helical tomotherapy and direct tomotherapy were compared. Helical tomotherapy provided better target volume coverage and OAR sparing than direct tomotherapy. CONCLUSIONS In a case of bilateral synchronous Stage 1 and Grade 1 breast cancer, helical tomotherapy appeared more suitable than direct tomotherapy.Entities:
Mesh:
Year: 2017 PMID: 28935854 PMCID: PMC5627865 DOI: 10.12659/ajcr.905245
Source DB: PubMed Journal: Am J Case Rep ISSN: 1941-5923
Planning target volume (PTV) of the right and left evaluated dosimetry for helical tomotherapy (HT) and direct tomotherapy (DT) with 1 cm and 0.5 cm expansion.
| D90% | 41.7 Gy | 41.4 Gy | 39.9 Gy | 41.4 Gy | 41.6 Gy | 41.4 Gy | 40.6 Gy | 40.7 Gy |
| D95% | 41.4 Gy | 40.8 Gy | 38.6 Gy | 40.8 Gy | 41.3 Gy | 41.1 Gy | 39.6 Gy | 39.8 Gy |
| D98% | 41.1 Gy | 40.1 Gy | 36.6 Gy | 39.4 Gy | 40.9 Gy | 40.1 Gy | 37.8 Gy | 37.0 Gy |
| D2% | 43.6 Gy | 43.8 Gy | 43.7 Gy | 43.3 Gy | 43.7 Gy | 44.1 Gy | 43.8 Gy | 43.6 Gy |
| Dmean | 42.4 Gy | 42.3 Gy | 41.9 Gy | 42.1 Gy | 42.3 Gy | 42.4 Gy | 42.1 Gy | 42.0 Gy |
| HI | 0.06 | 0.09 | 0.17 | 0.10 | 0.07 | 0.10 | 0.14 | 0.16 |
HT – helical tomotherapy; DT – direct tomotherapy; PTV right evaluation: – planning target volume evaluation for the right breast; PTV left evaluation – planning target volume evaluation for left breast; HI – homogeneity index.
Organ at risk (OAR) dosimetry for helical tomotherapy (HT) and direct tomotherapy (DT) with 1 cm and 0.5 cm.
| Right Lung | |||||
| V4 Gy | <50% | 76.1% | 75.5% | 42.5% | 53.7% |
| V8 Gy | <35% | 42.5% | 41.8% | 21.7% | 39.7% |
| V16 Gy | <15% | 19.2% | 22.1% | 14.4% | 20.8% |
| Dmean | 10.9 Gy | 10.9 Gy | 7.7 Gy | 10.1 Gy | |
| D2% | 39.2 Gy | 37.1 Gy | 34.7 Gy | 37.8 Gy | |
| Left Lung | |||||
| V4 Gy | <50% | 80.7% | 63.9% | 42.0% | 52.1% |
| V8 Gy | <35% | 44.8% | 42.1% | 23.2% | 33.4% |
| V16 Gy | <15% | 19.1% | 20.1% | 13.0% | 14.9% |
| Dmean | 11.1 Gy | 11.1 Gy | 7.3 Gy | 8.7 Gy | |
| D2% | 39.1 Gy | 40.7 Gy | 32.2 Gy | 38.1 Gy | |
| Heart | |||||
| Dmean | 4 Gy | 7.5 Gy | 7.9 Gy | 3.5 Gy | 6.0 Gy |
| D2% | 27.2 Gy | 27.1 Gy | 13.3 Gy | 20.7 Gy | |
| Spinal Cord | |||||
| Dmean | 3.7 Gy | 2.6 Gy | 1.9 Gy | 1.7 Gy | |
| D2% | <20 Gy | 7.6 Gy | 4.1 Gy | 3.1 Gy | 3.3 Gy |
| RVR | |||||
| V100% | 0% (0cc) | 0.008% (0.46cc) | 0% (0cc) | 0.341% (32.18cc) |
HT – helical tomotherapy; DT – direct tomotherapy; RVR – remaining volume at risk.